- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Stem Cell Trial May Resume Soon
28 August 2009 12:13 pm
Geron Corp. has revealed why the Food and Drug Administration halted its much-heralded Phase I clinical trial using embryonic stem cells to treat spinal cord injury 2 weeks ago. The reason: "non-proliferative cysts." In a statement issued yesterday, the company explained that in their ongoing animal studies, a small number of those injected with the stem cell preparation had developed tiny cysts at the injury site.
But not to worry, says Geron. That's actually good news. Spinal cord patients routinely develop much larger cysts. More significantly, there is no sign that the stem cell treatment causes tumors in the animals. And animal tests with a new batch of GRNOPC1, the stem cell preparation, showed no cysts. Geron officials expressed confidence that the trial will soon be back on track.